Survival After Hepatectomy for Combined Hepatocellular Cholagiocarcinoma
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 100
- 主要终点
- Survival analysis
研究概览
简要总结
Combined hepatocellular and mass-forming cholangiocarcinoma (cHCC-MFCCC) is a rare tumor. The aim of this study was the analysis of the outcome comparing such tumor with classic hepatocellular carcinoma (HCC) and mass-forming cholangiocarcinoma (MFCCC).
详细描述
The institutional prospectively maintained database was queried, and 20 patients with cHCC-MFCCC were identified. A 2:1 match was performed with 40 patients operated in the same period for HCC, and with 40 operated for MFCCC. Only T1 or T2 patients N0 M0 were considered. Primary endpoint was the overall survival (OS) and disease-free survival (DFS).
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •positive histology for cHCC-MFCCC, HCC, and MFCCC
- •complete clinical, surgical, pathological and follow-up data.
排除标准
- •patients preoperatively treated with chemotherapy, radiofrequency ablation or trans-arterial therapies were excluded.
- •patients operated for recurrent disease and/or with non-radical surgery
- •patients with missing data were also excluded
结局指标
主要结局
Survival analysis
时间窗: From 3 months after surgery up to 60 months after surgery
Analysis of overall and disease-free survival of patients resected for cHCC-MFCCC versus those resected for HCC versus those resected for MFCCC
次要结局
未报告次要终点
研究者
Prof. Guido Torzilli
Director of the Department of Hepatobiliary and General Surgery
University of Milan